Cell Medica announces first has been treated in CMV~ACE/ASPECT clinical trial.
The trial is a randomized, controlled study and will include36 patients across ten UK hospitals. Patients in the trial's treatment arm will receive CMV-specific memory T cells while patients in the control arm will receive only conventional antiviral treatment. The study is expected to be completed by the end of 2012 with results completed in 2013.
Cell Medica said the trial will complement an ongoing confirmatory Phase III study, CMV~IMPACT, which is investigating the use of adoptive cell therapy in bone marrow patients whose donors are siblings. The study is also being sponsored by Cell Medica and funded through Translation Award from The Welcome Trust.
In early January, the company signed an exclusive license agreement and research collaboration with the Center for Cell and Gene Therapy (CAGT), Baylor College of Medicine in Houston, for the commercialization of an innovative cell-based treatment for cancers associated with the oncogenic Epstein Bar virus (EBV). The goal of the collaboration is to establish a commercially viable fully GMP compliant manufacturing process as part of a plan to launch a confirmatory multicenter Phase II/III trial by 2012.
Contact: Gregg Sando, Cell Medica CEO, at Gregg.Sando@cellmedica.co.uk.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Clinical report|
|Date:||Feb 1, 2011|
|Previous Article:||Organ recovery systems begins commercial development for LifePort Liver Transporter.|
|Next Article:||Time has come for the transplant community to exorcise word "harvest" to describe the donation process.|